1、STATE OF AIIN BIOPHARMA2026THE STATE OF AI IN HEALTHCARE 2026Vi.coWritten&published by Vi Labs 2026A Vi Research Thought-Leadership ReportPublished January 2026ContentsTHE STATE OF AI IN PHARMA 2026P.02P.03P.04P.06P.10P.16P.20P.24P.26P.27P.29Executive SummaryPredictions for 2026Chapters:Chapter 1:Th

2、e Pharma AI Reset 2026Chapter 2:Where Pharma AI Is Actually Delivering Value in 2026Chapter 3:Technology Deep Dive:The AI Stack Reshaping PharmaChapter 4:The ROI Mandate:What“Good”Looks Like in 2026Chapter 5:Whats Next:20272028 OutlookFinal Notes for ReadersSources Glossary of TermsExecutive Summary

3、Biopharma enters 2026 at a structural inflection point.Scientific complexity,accelerating pipelines,omnichannel fragmentation,and rising development costs are making traditional operating models unsustainable.AI is moving from pilots into core commercial,clinical,and medical infrastructure,and it is

4、 now evaluated by measurable economic lift,not experimentation.This shift is driven by three advances:that executes multi-step workflows across the product lifecycle,that strengthen scientific and clinical reasoning,and r that make closed-loop execution possible at enterprise scale.agentic AI therap

5、eutics-tuned foundation models eal-time orchestration enginesKey Signals7080%of repeatable biopharma workflows shift to AI-orchestrated execution by 2028AI-enabled trials reduce cycle times by 1218%Protocol amendments add 46 months per trial on averageBringing a therapy to market now costs$2.3B$2.6B

6、Over 100,000 life-sciences papers are published each monthWhat Leaders Should Take AwayAI is becoming the operating layer for biopharma execution across development,medical,and commercial workflows.The organizations that win will be those that operationalize AI inside regulated workflows with measur